Coherus BioSciences CEO and leadership

Mr. Dennis M. Lanfear is a President and Chief Executive Officer at COHERUS BIOSCIENCES, INC. and is based in United States.

Preclinical and translational research leader with deep expertise and a record of success in R&D of first-in-class, bio-better and biosimilar therapeutics from discovery research through proof-of-concept (POC) clinical trials in oncology, inflammation, cardiovascular and virology therapeutic areas, and BLA and EMA submission and approval.

Core technical expertise in target review and prioritization, in nonclinical development strategies and in pharmacology and toxicology of biotherapeutics, translational and biomarker research, animal models, cell biology and immunology, bioanalytical and imaging technologies.

Experience in line and product management, management of cross-functional teams, in- and out-licensing, US and EU regulatory interactions, submissions and approvals.

McDavid Stilwell joined Coherus in October, 2020 and brings over 25 years of experience in finance, corporate development, investor relations, and communications.

Previously, he was Senior Vice President, Communications and Investor Relations at Sangamo Therapeutics. Prior to joining Sangamo Mr. Stilwell served as Vice President, Corporate Communications, Investor Relations & Business Development at Orexigen Therapeutics, Inc., and, from 2005 to 2012, as Director, Business Development, Corporate Communications and Financial Analysis at GTx, Inc. Earlier, Mr. Stilwell worked for five years as Senior Investment Analyst for Shadwell Capital, a hedge fund. Mr. Stilwell began his career as a journalist, first as a newspaper reporter and later, at SNL Financial, as editor of an investor newsletter covering financial services industry mergers and acquisitions. Mr. Stilwell received a B.A. from St. John’s College, Annapolis, Maryland, and a M.B.A. from Harvard Business School.

Mr. Hameister has more than 33 years of biopharmaceutical experience, leading both manufacturing and quality organizations, and having participated in the commercialization of more than 25 biologic and small molecule products. Prior to joining Coherus in 2016, he was the Vice President of Biologics Quality for Roche Pharma responsible for the Quality staff and functions for all commercial biologics manufacturing facilities and contract manufacturers worldwide. Prior to that role, Mr. Hameister served as the Vice President of Investigational Medicinal Product Quality for Roche Pharma, providing Quality staff and functional support for the Roche/Genentech clinical product portfolio from early stage development through commercialization.

Mr. Hameister is an active member of the Parenteral Drug Association and is a Retired Officer in the United States Army Reserve. He received his BS in Biological Sciences from the University of California, Davis.

Mr. Dennis M. Lanfear is a President and Chief Executive Officer at COHERUS BIOSCIENCES, INC. and is based in United States.

Mr. Dennis M. Lanfear is a President and Chief Executive Officer at COHERUS BIOSCIENCES, INC. and is based in United States.

Preclinical and translational research leader with deep expertise and a record of success in R&D of first-in-class, bio-better and biosimilar therapeutics from discovery research through proof-of-concept (POC) clinical trials in oncology, inflammation, cardiovascular and virology therapeutic areas, and BLA and EMA submission and approval.

Core technical expertise in target review and prioritization, in nonclinical development strategies and in pharmacology and toxicology of biotherapeutics, translational and biomarker research, animal models, cell biology and immunology, bioanalytical and imaging technologies.

Experience in line and product management, management of cross-functional teams, in- and out-licensing, US and EU regulatory interactions, submissions and approvals.